The Invisible Pharma Brand: Why Indian Generics Are Losing the AI Search Layer, and the 90-Day Fix

Every Indian pharma boardroom is talking about semaglutide. The originator patent has lapsed across most large markets, generic filings are accelerating and analysts continue to size the Glucagon-Like Peptide-1 (GLP-1) global opportunity at well over one hundred billion United States dollars by 2030. Eight Indian brands are likely to be commercial within the first sixty days of patent expiry in priority markets, and the formulation, regulatory and supply chain teams are doing what they have always done: filing, manufacturing and shipping.

The uncomfortable truth sits one floor away from the manufacturing site. When an endocrinologist in Riyadh, a procurement officer in Lagos or a patient in Toronto types "best semaglutide alternative" into ChatGPT, Perplexity or Google AI Overviews, the Indian brand is, in most cases, simply not present in the answer. The molecule is identical, the compliance is identical, the price advantage is real, and the brand is invisible.

This is the discoverability gap. It is not a marketing inconvenience. It is a strategic vulnerability that, left unaddressed, will hand market share to whichever competitor commits to authority publishing, structured content and AI-ready brand assets first. The same gap is already visible across biosimilars, oncology, cardio-diabetes and Over-the-Counter (OTC) categories. The window to close it is measured in quarters, not years.

"Patent expiry creates the legal right to compete. Discoverability creates the commercial ability to compete. Indian pharma has historically optimised for the first and assumed the second."

The good news is that the AI search layer is still being formed. Citation share is being earned in real time. Manufacturers that publish structured, citation-friendly authority content over the next two to three quarters will compound visibility for years. Manufacturers that delay will spend three to four times the budget later to claw back a position that could have been earned organically.

These three terms are often used interchangeably and that confusion is expensive. They are not the same discipline. They share infrastructure but optimise for different surfaces, different buyer behaviours and different success metrics. A serious pharma marketing function needs an explicit position on all three.

The strategic implication is that pharma marketing teams cannot pick one of the three. The buyer journey now crosses all three surfaces, often within a single research session. The brand that consistently appears across the SEO result, the AEO snippet and the GEO citation wins disproportionate trust, because repetition across surfaces is the modern equivalent of authority.

There is no global pharma marketing playbook. There are regional playbooks that share infrastructure. The publishing standard, evidence requirements and Healthcare Professional (HCP) engagement rules vary materially by jurisdiction and must be designed into the content template, not retrofitted at the legal review stage.

The operating principle is simple. Build a single global content engine, then expose region-specific surfaces, disclaimers and call-to-action paths from a shared compliance layer. The engine compounds. The exposure is local.

The following sequence is deliberately conservative. It is what a mid-size to large Indian generics or biosimilars manufacturer can realistically execute with a focused cross-functional team, an external content partner and existing regulatory infrastructure.

Every pharma demand-generation leader eventually faces the same fork. Build the discoverability engine in-house, buy it from an external specialist, or run a hybrid. The decision is rarely about cost. It is about speed to citation share, depth of regulatory governance and the appetite to carry fixed publishing infrastructure.

The hybrid model wins in nine of ten benchmarks we have run. The in-house team owns molecule strategy, regulatory sign-off and Healthcare Professional (HCP) relationships. The external partner owns structured publishing, schema engineering, Artificial Intelligence (AI) citation outreach and analytics. The shared dashboard prevents leakage between the two sides.

Use this quick model to estimate the incremental annual revenue from closing your citation gap. Toggle currency in the top floating bar to switch between United States Dollars (USD) and Indian Rupees (INR).

The wrong dashboard quietly destroys the program. Vanity traffic, generic rankings and undifferentiated impressions do not predict revenue in regulated categories. The following set of indicators is the minimum viable scorecard for a serious pharma demand-generation function.

Not every molecule earns the same digital investment. The matrix below is a starting point for triage. It is deliberately simple. The actual prioritisation in a portfolio review will incorporate margin, regulatory status, plant capacity and competitive density.

The operating model is where most programs quietly die. A capable in-house team paired with a specialist external partner outperforms a fully outsourced or fully in-house arrangement in every benchmark we have run. The reason is straightforward. Pharma marketing requires deep institutional knowledge of the molecule and deep operational knowledge of the publishing and AI surfaces. Very few organisations carry both at the depth required.

A practical split assigns molecule strategy, regulatory sign-off and HCP relationships to the in-house team, while structured publishing, schema engineering, AI citation outreach and analytics live with the external partner. A weekly operating rhythm, a single quality gate and a shared dashboard prevents the usual leakage between the two sides.

Equally important is the funding model. Treat the discoverability program as a portfolio investment, not a cost line. Re-prioritise quarterly based on citation share, HCP enquiry velocity and distributor Request for Quotation (RFQ) volume. Cut what is not compounding. Double what is.

10. Full Calculator Suite

The full calculator suite below is the same one used in our pharma engagements. Toggle United States Dollars (USD) and Indian Rupees (INR), switch languages, and run the math against your own assumptions. No sign-up, no email gate, no data leaves your browser.